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ABSTRACT
The use of bisphosphonate has become more widespread for the treatment 
of bone metastasis, multiple myeloma, osteoporosis, Paget's disease and other 
bone malignancies. Osteonecrosis of the jaw (ONJ) has been recently recognized 
as a possible complication of the use of bisphosphonate therapy. This study 
includes a review of the literature on the mechanism of action of bisphosphonate 
and its potential association to the development of osteonecrosis of the jaw. The 
inhibitory effects of bisphosphonates on osteoclasts and its antiangiogenic 
properties have been examined as possible mechanisms to induce osteonecrosis 
of the jaw. The incidence of ONJ in osteoporosis patients receiving 
bisphosphonate treatment is <1 in 100,000, and in between 1% and 10% in 
patients with malignancy (Hess et al., 2008). The results of this study suggest a 
higher incidence of osteonecrosis of the jaw in patients under long term use of 
nitrogen containing bisphosphonate. The incidence of bisphosphonate associated
v
ONJ in the first 4 to 12 months of therapy was of 1.5% and it increased to 7.7% 
after 37 to 48 months [Bamias] Additional risk factors include dental extractions, 
invasive dental procedures and trauma. It is not yet clear, however, if other 
drugs that affect bone turnover may induce similar complications. This study 
suggests an association of bisphosphonates to the development of osteonecrosis 
of the jaw. There is no evidence that bisphosphonates cause osteonecrosis of the 
jaw. An evaluation of the published data indicates that more research is 
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Introduction
Cancer cells can become highly invasive to the point of leading to bone 
metastasis, and greatly affecting the patient's life. Bone is the most common site 
for metastasis in cancer and the most common cancer to metastasize to bone is 
multiple myeloma, with 90% of patients developing bone lesions (Roodman, 
2004). Bone metastasis is also of particular clinical importance in breast and 
prostate cancers due to the prevalence of these diseases (Coleman, 2008). It is 
estimated that approximately 70% of patients with prostate or breast cancer will 
develop bone metastasis (Coleman, 2008). Prostate cancer bone metastasis is 
characterized by bone overgrowth, with lesions tending to appear on the axial 
followed by the appendicular skeleton. The complications of prostate cancer 
bone metastasis are very painful and include fractures and spinal-cord 
compression (Logothetis & Lin, 2005). Unlike breast cancer bone metastasis that 
leads to bone lyses, prostate cancer bone metastasis results in tumors that tend to 
be osteoblastic, and lead to the abnormal formation of bone. The set categories of 
metastatic tumor induced lesions in bone remodeling are: lytic, blastic, mixed
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lytic and blastic (McCauley & Schneider, 2003). The bone lesions of multiple 
myeloma are osteolytic in nature with decreased or completely absent 
osteoblastic activity (Roodman, 2004). Bone metastasis results from the activities 
of osteoblasts and osteoclasts, and the understanding of these interactions 
between the cancer cells with osteoblasts and osteoclasts is crucial to the 
development of therapies for these complications. An increase of osteoclastic 
activity increases bone resorption, and the inhibition of osteoblastic activity 
inhibits bone formation (Roodman, 2004).
Clinically, the consequences of this imbalanced mechanism in bone 
metastasis include bone pain, hypercalcemia, spinal cord compression, and 
pathologic fractures which contribute to the increase morbidity of the patient 
(Roodman, 2004). In order to prevent and treat the complications of bone 
malignancy, an anti-resorptive class of drugs known as bisphosphonates is 
currently used. Bisphosphonates have been around for more than 10 years for 
the treatment of osteoporosis and bone malignancy. In the absence of 
bisphosphonate therapy the annual fracture rates is of 20-40%, thus increasing 
the incidence of skeletal complications and contributing to skeletal morbidity
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(Coleman, 2008). About half of the patients who undergo bisphosphonate 
therapy demonstrate increased pain relief.
History of Pyrophosphates
In the 1960s Fleisch investigated the bone resorption capacity of sodium 
pyrophosphates and other inorganic pyrophosphates (PPi), and concluded that 
PPi prevented body fluid calcification by binding to hydroxyapatite crystals. 
One of the disadvantages of the oral form of PPi was that it was inactivated by 
phosphatases secreted by the gastrointestinal brush border (Gutta & Louis). In 
an attempt to develop a drug that would withstand hydrolysis and be more 
stable, a synthetic form of the drug was developed. Bisphosphonates are 
synthetic, nonhydrolyzable analogues of PPi which are able to be tolerated in the 
oral route and remain active. Like its precursor PPi, they are also able to inhibit 
the dissolution of hydroxyapatite crystals (Gutta & Louis, 2007). 
Bisphosphonates inhibit osteoclastic differentiation and activity, and are potent 
anti-resorptive agents used in metabolic bone disorders. This class of drug has 
been used in the treatment of osteoporosis, Paget's disease and metastatic bone
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cancer because of its anti-resorptive capacity and anti-tumor properties (Wang, 
Weber, & McCauley, 2007).
Structure of Bisphosphonates
The ability of bisphosphonates to bind to bone and inhibit osteoclastic 
resorption is explained in part by its P-C-P structure, which readily binds to 
metal ions such as Ca2+. The preferential localization to bone and its high 
affinity for bone is due to the presence of a hydroxyl group at the R1 chain (Gutta 
& Louis). One of the ways that manufactures produce more potent compounds 
is by manipulating the R2 side chain (Gutta & Louis, 2007). There are two forms 
of bisphosphonates those containing the amino group and those non-nitrogen 
containing bisphosphonates. The most powerful bisphosphonates are amino- 
bisphosphonates such as zoledronic acid. The amino- containing 
bisphosphonates include: zoledronic acid, pamidronate, ibandronate,
risedronate, and alendronate (Wang et al., 2007). The non-amino containing 
bisphosphonates are: etidronate, clodronate, and tiludronate (Wang et al., 2007) 
(Figure 1). Its P-C-P structure provides the stability necessary to bind to bone
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mineral surface as well as to withstand hydrolysis and be rapidly cleared from
the circulation (Pazianas, Miller, Blumentals, Bernal, & Kothawala, 2007)/(Gutta 
& Louis, 2007).
Mechanisms of Bisphosphonates 
Non-amino BPs
The inhibitory effects of bisphosphonates occur through multiple 
pathways and at different steps depending on the nature of the drug. The first- 
generation bisphosphonates closely resemble PPi, and are non-nitrogen 
containing bisphosphonates. Clodronate and etidronate are among these simple 
bisphosphonates, and they are able to inhibit bone resorption by inducing 
osteoclast apoptosis (Wang et al„ 2007)/(Roelofs, Thompson, Gordon, & Rogers,
2006). The internalization of bisphosphonates by osteoclasts disrupts osteoclast 
function and results in apoptosis of the cell (Coleman, 2008). The mechanism by 
which this class of bisphosphonates induces osteoclast apoptosis includes the 
intracellular conversion of non-nitrogen containing bisphosphonates into an ATP
analogue, AppCp-type (Roelofs et al„ 2006). The accumulation of the AppCp-
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type metabolite in vitro was shown to inhibit bone resorption and induce 
osteoclast apoptosis (Roelofs et al., 2006). Non-nitrogen containing 
bisphosphonates inhibit bone resorption mainly through this apoptotic pathway. 
In vitro experiments give evidence that this apoptotic mechanism fails to work 
after the introduction of a caspase inhibitor. The Mammalian Sterile 20-like (Mst) 
kinase is a substrate for caspase 3 in many hematopoietic cells and can induce 
apoptosis in mesenchymal cell lines (Reszka, Halasy-Nagy, Masarachia, & 
Rodan, 1999). A study by Rezka et al suggested that the Mst kinase 1 is part of 
the signaling pathway that leads to apoptosis, and that the cleavage of the Mst 1 
has a high catalytic activity. Non-nitrogen containing bisphosphonates such as 
clodronate are able to induce osteoclast apoptosis by induction of Mst 1 cleavage 
at higher concentrations of the compound (Reszka et al., 1999).
Nitrogen-containing bisphosphonates (N-BPs)
The Mst 1 cleavage can also be done with N-BPs via another mechanism, 
the mevalonate pathway. (Reszka et al., 1999)/(Wang et al., 2007). The 
mevalonate pathway is an important cellular metabolic pathway because the
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formation of mevalonate from acetyl-CoA is the committed step in the 
cholesterol biosynthesis pathway (Garrett & Grisham). The rate-limiting step to 
the action of N-BPs is thought to be geranyl diphosphate (GGOH) in this 
pathway. According to Rezka et al, GGOH is able to prevent: the inhibition of 
bone resorption, induction of Mst 1 kinase cleavage and the induction of 
apoptosis by alendronate and risedronate. The mevalonate pathway is
responsible for post-translational modifications and intracellular vesicular 
transport (Wang et al., 2007). A crucial step of the mevalonate pathway is the 
conversion of geranyl pyrophosphate into farnesyl pyrophosphate (Wang et al., 
2007). Farnesyl diphosphate (FPP) synthase is the key enzyme to act on this step 
and it is also the target for inhibition of the pathway by nitrogen-containing 
bisphosphonates (Roelofs et al., 2006).
In N-BPs the build up of apoptotic metabolites occur through the 
inhibition of farnesyl pyrophosphate (FPP) formation, which leads to the build 
up of isopentenyl diphosphate (Wang et al., 2007). Isopentenyl diphosphate can 
be converted into an apoptotic metabolite, Appi, an intracellular ATP analogue 
(Wang et al., 2007). Appi and AppCp-type analogues induce osteoclast 
apoptosis similarly. As a result of the inhibition of this key enzyme of the
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mevalonate pathway, bone resorption is compromised (Wang et al.,
2007)/(Roelofs et al., 2006). One of the first steps required for bone resorption to 
occur is the formation of a ruffled border (Wang et al., 2007). Inhibition of the 
mevalonate pathway interferes with post-translational modifications and 
activation of small G-proteins needed for proper intracellular vesicular transport 
required for the ruffled border formation in osteoclasts (Wang et al., 2007). 
Alakangas et al demonstrated that the use of alendronate disrupts the trafficking 
of vesicular transport in osteoclasts such that they are not able to fuse to bone.
As a result of the inhibition of FPP synthase, bone resorption is 
compromised (Wang et al., 2007)/(Roelofs et al., 2006). Nitrogen-containing 
bisphosphonates (N-BPs) such as zoledronic acid are potent inhibitors of this 
enzyme, and only nanomolar concentrations of N-BPs are necessary for the 
inhibition of FPP synthase (Roelofs et al., 2006). By inhibiting the FPP synthase, 
FPP and geranylgeranyl diphosphate are also inhibited. Thus, the inhibition of 
FPP synthase prevents the prenylation of small GTPases once the production of 
the building blocks required for the prenylation has been inhibited. These small 
GTPases are important signaling proteins and they include Ras, Rho and Rab
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families. They play an important role in the regulation of key cell processes for 
osteoclast function.
Fisher et al investigated the direct effects of N-BPs in the mechanism of 
inhibition of the FPP synthase in vivo. The expression of hydroxymethyl- 
glutaryl-coenzyme A reductase (FFMGR) is tightly regulated by FPP and other 
metabolites of the mevalonate pathway. This immunohistochemistry study 
measured the expression of HMGR of male rats proximal tibiae. The results gave 
supporting evidence to the previous in vitro studies in which N-BPs act via the 
mevalonate pathway to inhibit bone resorption and interfere with osteoclast 
activity. The control group of this study had 82% of all osteocytes stained for 
HMGR, while the group treated with alendronate had 20% of osteocytes 
positively expressing HMGR. This study also confirmed the difference in the 
mechanism of action between N-BPs and non-nitrogen containing 
bisphosphonates. N-BPs such as Alendronate, Risedronate, and Ibandronate 
were compared to non-nitrogen containing bisphosphonates such as Clodronate 
and Etidronate.
The fraction of osteocytes stained for HMGR was reduced by 67-76% in 
the N-BPs group compared to the vehicle. The non-nitrogen containing
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bisphosphonate group accounted for a slight, but non-significant increase of 
positively stained osteocytes. To quantify for osteocyte numbers a statistical 
analysis was performed of the number of HMGR-positive osteocytes determined 
by a light microscope divided by the total number of osteocytes of the primary 
spongiosa region. The evidences from this in vivo study confirm that N-BPs 
inhibit the FPP synthase of the mevalonate pathway in the same way as in vitro. 
The non-nitrogen containing bisphosphonates were not able to inhibit the FPP 
synthase in vitro or in vivo as confirmed by this study. N-BPs inhibit bone 
resorption mainly by inhibiting the FPP synthase step of the mevalonate 
pathway which interferes with the prenylation of proteins crucial to the signaling 
and regulation of osteoclast function (Roelofs et al., 2006).
Properties of Bisphosphonates -  Angiogenesis 
Antiangiogenic effects ofBPs
In addition to inducing osteoclast apoptosis, bisphosphonates have also
been shown to have antiangiogenic effects (Roelofs et al., 2006)/(Gutta & Louis,
2007). Angiogenesis is defined as the formation of new blood vessels from pre-
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existing vessels and it has been suggested to be essential for solid tumor growth 
(Kufe & Bast, 2003)Tumor progression is driven by the accumulation of genetic 
damage from mutated genes, and the development of sustained angiogenesis is 
among the traits that sustain the progression of the malignancy (Kumar & 
Robbins, 2007). Vascularization is necessary for tumor growth since it requires 
nutrients, oxygen and removal of waste for its survival and enlargement (Kumar 
& Robbins, 2007). Research has shown that tumors cannot enlarge beyond 1 to 
2mm in diameter unless they are vascularized, and cells can also be stimulated 
by growth factors released from endothelial cells to sustain continued tumor 
growth (Kumar & Robbins, 2007).
Angiogenesis plays a crucial role also in the increase of access to 
vasculature and metastasis (Kumar & Robbins, 2007). In order for tumor 
angiogenesis to take place, several angiogenic factors are required (Zhang, Lu, 
Beech, Jiang, & Lu, 2007). Vascular endothelial growth factor (VEGF) is one of 
the most potent angiogenic factors, and it promotes an increase in vascular 
permeability (Santini et al., 2003). The balance between the angiogenic factors 
and angiogenesis inhibitors is necessary to maintain tumor angiogenesis (Kumar 
& Robbins, 2007). Some of these angiogenic factors, such as VEGF, induce
11
angiogenesis in response to hypoxia (Kumar & Robbins, 2007). Increased rates of 
invasion and metastasis have been associated with increased expression of 
VEGF. The level of VEGF in the blood may be predictive of metastases and 
response to chemotherapy (Kufe & Bast, 2003). The inhibition of VEGF has been 
shown to decrease tumor growth in vivo (Santini et al., 2003). Vascular 
endothelial growth factor (VEGF) is also an important signaling protein involved 
in endothelial cell mitogenesis and cell migration (Santini et al., 2003).
Mitogens bind to cell-surface receptors in the form of signaling proteins, 
and they are responsible for the activation of intracellular signaling pathways 
through this mechanism. One of the first mitogens identified is platelet-derived 
growth factor, or PDGF. PDGF is an example of a mitogen released by platelets, 
and they are able to bind to tyrosine kinase receptors and stimulate surviving 
cells of an injury site to proliferate and promote wound healing (Alberts, 2004). 
Several studies investigate the antiangiogenesis effects of zoledronic acid and its
antitumoral mechanism.
Scavelli et al suggest that the antiangiogenic effect of zoledronic acid in 
multiple myeloma may account for its antitumoral activity. Multiple myeloma is 
a tumor of terminally differentiated plasma cells, and plasma cells secrete
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mgiogenic factors such as vascular endothelial growth factor (VEGF) and basic 
fibroblast growth factor (bFGF). Plasma cells work as primary inducers because 
they secrete the major angiogenic factors. There is also another type of 
angiogenesis inducer called secondary inducer, which functions by recruiting 
and activating plasma cells (Scavelli et al., 2007). A secondary inducer known as 
multiple myeloma patient-derived endothelial cells (MMECs) participates in the 
angiogenesis pathway of VEGF/VEGF receptor-2, and it is through an autocrine 
loop that multiple myeloma angiogenesis is supported (Scavelli et al., 2007). An 
autocrine loop is a pathway in which cells secrete factors such as VEGF, and 
these secreting cells respond to the secreted factor due to the presence of 
functional cognate receptors on the secreting cells. The inhibition of the 
VEGF/VEGF receptor- 2 pathway may be effective in promoting antiangiogenic 
activity. One of the studies analyzed the capillarogenesis on matrigel of MMECs, 
VEGFi65, zoledronic acid and a control group (Scavelli et al., 2007). In this assay 
the angiogenesis inducing compound VEGF165 in serum free medium was 
introduced on a Matrigel and compared to the combination of VEGFms and 
zoledronic acid at two different doses (Akhtar, Dickerson, & Auerbach, 2002). 
The purpose of the study was to determine the antiangiogenic properties of
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zoledromc acid through the proliferative response of MMECs in two distinct 
MMEC conditioned media (Akhtar et al., 2002).
Zoledronic acid was shown to be very effective in the inhibition of 
capillarogenesis on the matrigel. This assay works by injecting tumor cells or 
angiogenesis inducing compounds into a cold liquid Matrigel which is injected 
subcutaneously in the mouse (Akhtar et al., 2002). After the subcutaneous 
injection of the Matrigel in the mouse, the Matrigel solidifies and interacts with 
the host cells and new blood vessels form. The assay protocol for this particular 
experiment involved the injection of the Matrigel in the midventral abdominal 
region of a 2.5-3.5 month old mouse (Akhtar et al., 2002). After the Matrigel 
solidified the mouse was anesthesized and a small incision was made so that a 
sterilized polyvinyl sponge with FGF or tumor cells could be placed in between 
the skin and over the Matrigel (Akhtar et al., 2002). The suture is closed and 
monitored for 24 hours, and typically the results of the b-FGF angiogenesis 
inhibition can be measured after 7 days (Akhtar et al, 2002).
The matrigel assay has been widely used in vivo studies on angiogenesis. 
One of the advantages of this assay in comparison to previous ones is that it does 
not involve surgery and it is not very time consuming (Akhtar et al., 2002). This
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assay allows for better visualization of the angiogenic reaction, and the 
assessment of the reaction can be done by determining the hemoglobin content 
(Akhtar et al., 2002). It is also possible to assess angiogenic reactions in the 
Matrigel by histological examination of the selected sections stained for blood 
vessels (Akhtar et al., 2002).
Zoledronic acid added to the media of chorioallantoic membranes treated 
with a sponge loaded with MMECs or VEGF165 also significantly inhibited the 
angiogenic response (Scavelli et al., 2007). This assay was done with fertilized 
white leghorn chicken eggs incubated at 37 Celsius at constant humidity (Scavelli 
et al., 2007). On the third day 2 to 3 mL of albumen is collected via a square 
window opened in the shell. This procedure is necessary to allow detachment of 
the chorioallantoic membrane (Scavelli et al., 2007). Three kinds of sterilized 
gelatin sponges are prepared to be implanted, and one of them is loaded with 1 
AL of PBS for negative control (Scavelli et al., 2007). The second sterilized 
gelatin sponge is loaded with 1 AL of PBS and 250ng of VEGF for positive 
control. The third sterilized gelatin sponge is loaded with 1 AL of culture 
conditioned media from MMECs alone or added with 10 or 30 Amol/L 
zoledronic acid (Scavelli et al., 2007). These sterilized gelatin sponges are
15
implanted on the eighth day in the chorioallantoic membranes to evaluate the 
angiogenic response at day 12 of implantation (Scavelli et al., 2007). The number 
of blood vessels converging toward the sponge is evaluated through 
photographs done with an Olympus stereomicroscope (Scavelli et al., 2007).
Some reasons why chorioallantoic membrane assays are preferred for 
angiogenesis quantification include its practicability for being simple and for 
allowing a greater number of samples to be screened at one time (Ribatti, Nico, 
Vacca, & Presta, 2006). In addition, the chorioallantoic membrane assays are 
cheaper than other techniques of the same kind. One of the difficulties of this 
technique is that the material to be tested is placed on top of the pre-existing 
vessels so quantifying for angiogenesis requires careful measurements (Ribatti et 
al., 2006). The morphometric model can be used histologically as part of the 
microscopic technique. Some macroscopic evaluations include the analysis of 
branching blood vessels, quantification of the density of the chorioallantoic 
membrane and analysis of the variation in distribution of the new blood vessels . 
The allantoic vessels developed well in media treated with VEGFies or MMECs. 
Scavelli et al suggest that the antitumoral activity of zoledronic acid is related to 
its antiangiogenic capacity (Scavelli et al., 2007). The chorioallantoic membrane
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assay is an effective method for analyzing the activity of angiogenic inhibitors 
and stimulators in vivo.
Santini et al investigated the potential antiangiogenic effect of zoledronic 
acid in its antitumor activity in patients undergoing cancer treatment. In order to 
control for the blood cytokine levels in response to zoledronic acid, these patients 
weie not taking any chemotherapeutic drugs or steroids. The blood cytokine 
levels were measured before the infusion of zoledronic acid and also 1, 2, 7, and 
21 days after the first infusion. The results of this study for VEGF showed a non- 
statistically significant decrease (6.5%) after the zoledronic acid infusion after the 
first day. On the second day the decrease of VEGF compared to basal level 
reached 23% and was followed by a greater increase of 28% on the seventh day 
after the first administration. Twenty-one days after the first zoledronic acid 
infusion the results remained lower, marking a 34% decrease of VEGF in 
comparison to the basal level. These results were significant and demonstrated 
the ability of zoledronic acid to maintain a long-lasting decrease as a potent 
angiogenic factor. On a similar study with the administration of pamidronate, it 
was observed a significant decrease of the VEGF level versus the basal level
17
(Santini et al., 2002). Zoledronic acid, however, demonstrated a lasting and 
longer decrease of VEGF in comparison to pamidronate (Santini et al., 2002).
The percentage change of PDGF versus the baseline showed a significant 
decrease after the first day of zoledronic acid administration. After the first day 
the percentage decrease reached 25% and it was followed by 30% on the second 
day. On the seventh day the PDGF values returned to the normal basal level and 
remained that way on the twenty-first day as well. The platelet level as well as 
the white blood cell (WBC) count and hemoglobin concentration did not change. 
The medium calcium level, however, decreased from 11.04mg/dL to 8.45mg/dL 
seven days after the zoledronic acid administration. The findings of this study 
regarding the antiangiogenic effect of zoledronic acid are also supported by an in 
vitro study. Wood et al developed an in vitro model in which human endothelial 
cells were stimulated to proliferate by fetal calf serum, basic fibroblast growth 
factor (bFGF), and VEGF. The study reported that the addition of zoledronic 
acid to the human endothelial cells inhibited their proliferation. Rat aortic rings 
culture ex vivo in collagen gels and chicken egg chorioallantoic membrane 
treated with zoledronic acid also indicated inhibition by zoledronic acid. These 
studies confirm the antiangiogenic properties of both pamidronate and
18
zoledronic acid through an inhibition of VEGF angiogenic activity. The dose 
dependent administration of zoledronic acid also inhibited bFGF and, thus, 
zoledronic acid may be anti-angiogenic to via bFGF and PDGF besides VEGF 
(Wood et alv 2002). The mechanism by which zoledronic acid induces 
angiogenesis may be different for bFGF and VEGF once their sensitivity to the 
zoledronic acid differs (Wood et al., 2002). Wood et al speculate that the anti- 
angiogenic effects of zoledronic acid are generally more cytotoxic in the VEGF 
pathway, making not as sensitive to zoledronic acid as bFGF (Wood et al., 2002). 
Wood et al show that the angiogenic effects of PDGF, bFGF, and VEGF may be 
inhibited by zoledronic acid.
Another in vivo study by Santini et al reported a decrease in the 
circulating levels of VEGF in cancer patients treated with bisphosphonates. 
Patients with cancer and bone metastasis who were not under radiotherapy, 
chemotherapy or steroids were selected for the study (Santini et al., 2006). The 
aim of this study was to examine the correlation between the circulating levels of 
VEGF and a marker of bone resorption known as 6 crosslinked type I collagen C- 
telopeptide (fiCTX) (Santini et al., 2006). An assay for the fiCTX bone resorption 
marker was used because studies have shown that type I collagen is the
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predominant protein in bone (Brown et al., 2003). Studies have indicated a 
correlation between bone metastasis and collagen breakdown markers (Brown et 
alv 2003). It has also been demonstrated that N-telopeptide (Ntx) bone markers 
increase in patients with skeletal events that lead to bone resorption such as bone 
metastasis and osteoporosis (Brown et al., 2003). These bone markers are 
characteristic of collagen breakdown as opposed to collagen synthesis. 
Zoledronic acid was the drug of choice because its administration in cancer 
patients with bone metastasis has shown a rapid decrease in bone resorption 
markers according to previous studies.
The levels of VEGF and 6CTX were measured at baseline and 1, 2, 7 and 
21 days after zoledronic acid infusion. Results of the study have shown that the 
fiCTX basal level decreased by 67% reaching 76% decrease by the last day 
(Santini et al., 2006). The median decrease of fiCTX was significant, 67%. Unlike 
the bone resorption marker, fiCTX, there was no significant decrease in the VEGF 
level after the first day of zoledronic acid infusion. After the second day of 
administration of the drug, the level of VEGF dropped significantly (24%) and 
remained low until the last day (39%) (Santini et al., 2006). The analysis of the 
results with a linear regression model between the basal VEGF values and fiCTX
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values did not produce a positive correlation between the two values (Santini et 
alv 2006). A correlation between the two variables quantifies how well the two 
variables are related, but it does not necessarily explain a causal and effect 
relationship between them (Suporn, 2008). At each of the time points, however, 
the results indicate a positive correlation between the median VEGF and the 
circulating levels of SCTX (Santini et al., 2006). The magnitude and the direction 
of the two variables were positive, thus indicating a positive effect between 
them, but no causal effect (Santini et al., 2006)/(Suporn,2008).
The results indicate that the median basal VEGF values and the ECTX 
circulating levels are related at the time points. A statistically significant 
correlation persisted for 21 days, reaching the highest level of significance at the 
seventh day (Santini et al., 2006). A strong and direct correlation after the first 
day of zoledronic acid infusion was also reported. These data suggest that 
zoledronic acid plays a crucial role in the treatment of bone metastasis and 
reinforces its antitumoral properties, because both angiogenesis and bone 
resorption appear to be inhibited by zoledronic acid.
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Complications of bisphosphonates
Bisphosphonates can be taken orally or via intravenous administration, 
and generally it is well tolerated (Reiriz, De Zorzi Pde, & Lovat, 2008). Patients 
with bone metastasis have been treated with pamidronate (90mg) infused for at 
least 2 hours every 3-4weeks for over the past ten years. In 2001 the FDA 
approved the use of a potent N-BP known as zoledronic acid (Khosla et al., 2007). 
Zoledronic acid infusions last 15 minutes and the dose of 4 mg is repeated 
monthly (Ruggiero, Mehrotra, Rosenberg, & Engroff, 2004). Some critical side- 
effects have, however, been reported from the intravenous administration of the 
drug (Reiriz et al., 2008). Among the most serious side-effects reported from 
intravenous administration especially at higher doses and infusion rates is acute 
renal failure (Wang et al., 2007). The elevation of the creatinine levels may lead to 
impairment of renal function especially in patients with a history of kidney 
disease (Migliorati, Schubert, Peterson, & Seneda, 2005). Bisphosphonate therapy 
is typically indefinite if well tolerated by the patient (Ruggiero et al., 2004). The 
general flu-like symptoms, fatigue, anemia, dyspnea and edema are common 
reactions (Migliorati et al., 2005). Gastrointestinal toxicities, esophagitis.
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mucositis and nausea are additional side-effects that have also been reported 
from oral intake of the drug (Reiriz et al., 2008)/(Wang et al., 2007). The oral 
intake of bisphosphonate is indicated for patients with osteoporosis because 
although potent, they are not as efficient in the treatment of a malignant 
osteolytic disease (Ruggiero et al., 2004). The oral bisphosphonates that can also 
be taken intravenously are: clodronate and ibandronate. Other bisphosphonates 
taken orally are: tiludronate, risedronate, and alendronate. Recently, studies 
have reported the association of bisphosphonate with a new complication: 
avascular osteonecrosis of the jaw (Reiriz et al., 2008)/(Wang et al., 2007).
ONJ as a complication of bisphosphonates
Osteoradionecrosis, or osteonecrosis of the jaw associated with radiation 
therapy, has long been documented and occurs in less than 3% of patients with 
head and neck cancer (Hoff et al., 2008). The possible association of 
bisphosphonates and osteonecrosis of the jaw as a complication to the therapy is 
a new area of study based on the increased number of reported cases (Khosla et 
al., 2007) A task force from the American Society for Bone and Mineral Research
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(ASBMR) has carefully reviewed relevant published studies on the potential 
association of bisphosphonates-ONJ and has offered a definition for this disorder 
(Khosla et al., 2007). Bisphosphonate-associated ONJ is defined as an area of 
exposed bone in the maxillofacial region present for at least 8 weeks in a patient 
under bisphosphonate treatment who has not received radiation therapy in the 
craniofacial region (Khosla et al., 2007)/(King & Umland, 2008). A suspected case 
of bisphosphonate-associated ONJ is defined as an area of exposed bone in the 
jaw or face that has not healed and has been present for less than 8 weeks after 
observed by a health care provider (Khosla et al., 2007). The patient must also be 
receiving bisphosphonate therapy and have not had radiation therapy to the 
craniofacial region (Khosla et al., 2007). The 8 week period necessary to 
determine a confirmed case of ONJ is determined from the time exposed bone is 
first identified (Khosla et al., 2007). This duration period is explained by the 
natural healing process that results in soft tissue closure after oral surgery, teeth 
extraction, other invasive treatments or trauma.(Khosla et al., 2007). In a healthy 
human being the complete healing process should be completed by 8 weeks.
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Healing
Landesberg et al investigated the effect of pamidronate in oral mucosa 
cells to better understand the effect of bisphosphonates in the healing process. 
Landesberg et al propose a new approach to the mechanism of ONJ in which this 
complication secondary to bisphosphonate may arise from the oral mucosa as 
opposed to bone. The hypothesis is that after a trauma or invasive dental 
procedure the bisphosphonate concentration at the site of the trauma increases 
(Landesberg et al., 2008). This increase in bisphosphonate due to trauma is 
supposed to inhibit normal epithelial wound healing and lead to ONJ 
(Landesberg et al., 2008).
The aim of this study was to determine if bisphosphonates such as 
pamidronate could inhibit mucosal cell proliferation and interfere with wound 
healing (Landesberg et al., 2008). Apoptosis assays were performed to 
understand the mechanism of interaction between the drug and oral mucosa cells 
(Landesberg et al., 2008). A proliferation assay measured the effects of 
pamidronate over 24, 48, 72, and 168 hours on the murine oral keratinocytes
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isolated (Landesberg et al., 2008). The concentrations of pamidronate used were 
0.003, 0.01, 0.03, 0.1 mM and the control group (Landesberg et al., 2008). The 
level of pamidronate at 0.1 mM is the same as the one that should be present in 
the oral mucosa of a patient receiving the intravenous therapy (Landesberg et al.,
2008). The results of this assay show that pamidronate at O.lmM level of 
concentration inhibits cell proliferation and all the other concentrations below do 
not interfere with cell growth (Landesberg et al., 2008). A wound healing assay 
measured the ability of the pre-incubated murine oral keratinocytes to proliferate 
and migrate (Landesberg et al., 2008). Those cells pre-incubated with 
pamidronate at the 0.003, 0.01 and 0.06 mM successfully completed the healing of 
the wound at 72 hours (Landesberg et al., 2008). At the 0.1 mM concentration of 
pamidronate the wound closure was significantly delayed (Landesberg et al., 
2008). According to the apoptosis assays, however, the effects of inhibition of 
proliferation and delayed wound healing were not due to apoptosis (Landesberg 
et al., 2008). This type of in vitro study has not been widely published and more 
investigation on the mechanism of action of bisphosphonates is necessary 
(Landesberg et al., 2008).
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A case report by Wang et al supports the need to better understand the 
effects of bisphosphonates in the skeleton and its cumulative effect (Wang et al., 
2007). Fifty percent of the administered bisphosphonate is sequestered in bone 
and its half-life can range from years to months (Wang et al., 2007). This case 
report shows that a patient being treated with bisphosphonates for more than ten 
years can suffer from longer-term complications possibly associated with the 
drug. This report also highlights how a change in bisphosphonate medication 
can compromise the healing process after an implant (Wang et al., 2007). The 
reported case was of a 65-year old woman with a history of osteoporosis being 
treated with alendronate for over ten years. The diagnosis for this patient 
included: generalized mild chronic periodontis, gingival recession, mandibular 
partial endentulism and maxillary complete endentulism. A tooth extraction and 
implants were part of the treatment plan for this patient. The socket of the tooth 
extracted seemed to have healed normally and the implants were placed a month 
after the extraction. Ten days after the implants were placed, the patient was 
evaluated and no abnormalities were found. Six weeks after the implants, 
however, the patient was found to have suppuration and X-ray radiolucency 
around the apex of two implants. At the time of the surgical evaluation of the
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bone around the implants the patient reported a change in the medication that 
occurred around the fourth week after implant surgery. The patient had been 
taking oral alendronate for over ten years for osteoporosis and changed to 
teriparatide.
The reason for the compromised healing is not clear, but the new 
medication may have contributed to the impaired healing of the implants 7 
weeks after the surgery. The bone was necrotic, degranulated and there was a 
huge pocket without bone between two implants. Six months after post­
corrective surgery the osseointegration and complete healing was achieved. The 
patient was able to complete the treatment with a prosthetic restoration. The 
compromised healing 7 weeks postoperative is thought to be associated with the 
medication change, but the mechanisms are not clear. Osteoporosis by itself was 
not shown to pose a risk on the success of dental implants (Wang, Weber, & 
McCauley, 2007). Although osteoporosis patient often fear complications, 
studies have suggested that dental implants in the lower jaw are not affected. A 
study by Friberg et al reported a 97% success rate of implants in both the maxilla 
and mandible of osteoporosis patients after 3 years. There is not a lot of 
information on the impact of bisphosphonate therapy and implants for these
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patients. 1 he case report by Wang et al discussed above presents a patient who 
was under long-term use of bisphosphonates and switched medications to 
teriparatide. Teriparatide is used to prevent fractures in both men and women 
with osteoporosis. It is a synthetic parathyroid hormone (PTH), and PTH plays 
an important role in bone turnover. Teriparatide instead of being antiresorptive 
as bisphosphonates, it is anabolic for bone. In order to better understand the 
effects of bisphosphonates and PTH in bone an overview of bone remodeling 
may be useful.
Bone Remodeling
Bisphosphonate use in metastatic cancer effect on bone is explained in 
part by its effect on the bone microenvironment. Its ability to interfere with 
bone remodeling makes the bone microenvironment less favorable to tumor 
growth (McCauley & Li, 2007)/(Green, 2004). Bone remodeling involves the 
balance between the activities of osteoclasts and osteoblasts in bone. Osteoclasts 
are responsible for bone resorption and originate in the hemapoietic granulocyte- 
macrophage colony forming unit, while the osteoblasts involved in bone
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formation originate from pluripotential mesenchymal stem cells (Gonzalez, 
2000). Bisphosphonate composition allows for strong affinity for bone and the 
inhibition of bone resorption. Bisphosphonates induce osteoclast apoptosis after 
incorporation into osteoclastic cells. The process of bone resorption and bone 
formation is characterized by the resorption of the bone cavity by osteoclasts and 
formation of bone on those same cavities by osteoblasts that lay down matrix 
that is later mineralized.
The regulation of the bone remodeling system include the interaction of 
factors such as RANK ligand (RANKL) and RANK receptor that increase 
osteoclast differentiation. RANKL and RANK receptors are members of the 
tumor necrosis factor (TNF) and TNF receptor families, respectively (Zhang et 
al., 2001). RANKL is an osteoblast-specific cell surface protein that interacts with 
the RANK receptor on the undifferentiated osteoclast, causing osteoclast 
differentiation, bone resorption, and hypercalcemia. The interaction between 
RANKL and the RANK receptor can be inhibited by Osteoprotegerin (OPG), a 
decoy receptor that is produced and secreted by the osteoblast and binds to 
RANKL. Studies have shown that OPG knockout mice develop severe 
osteoporosis, thus reinforcing the role of OPG as a critical regulator of
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osteoclastogenesis (Zhang et al., 2001)/ (Lee & Lorenzo, 1999). The activity of 
osteoclasts is regulated by the ratio of RANKL to OPG, and too much production 
of OPG causes osteopetrosis (Roodman, 2004). Osteopetrosis is a condition that 
is the opposite of osteoporosis because the bones are extremely hard and dense. 
The intermittent delivery of PTLI decreases the ratio of RANKL to OPG, causing 
bone formation (Wang et al., 2007). Osteopenia is the precursor for osteoporosis 
because it is marked by decreased bone density. The continuous delivery of PTH 
increases the ratio of RANKL to OPG and stimulates bone resorption (Wang et 
al., 2007). In the case of the patient discussed above it is not known how 
teriparatide may compromise mineralization and healing. Wang et al discuss a 
possible interference of a rise in PTH level in the presence of bisphosphonates. 
Bisphosphonates induce hypocalcemia and studies suggest that an increase in 
the level of PTH followed by hypocalcemia may lead to osteonecrosis of the jaw 
(ONJ) secondary to bisphosphonate (Wang et al., 2007). It is not clear, however, if 
the interaction of these drugs support this hypothesis once patients on 
alendronate do not have hypocalcemia or elevated PTH level (Wang et al., 2007). 
Although the mechanism of action of these two drugs may differ, more in vivo 
studies would be necessary to understand their interaction. In vivo studies are
31
essential to clarify the impact of bisphosphonates and other drugs that induce 
bone turnover in bone. Anti-resorptive drugs such as teriparatide, which are 
used in patients with osteoporosis, must also be investigated.
Signs/Symptoms
According to Migliorati et al some of the signs and symptoms that bring 
patients to the clinic are pain and discomfort in the teeth and gums. Although 
this type of osteonecrosis has not been associated with bone metastasis, some 
patients seek their doctors concerned that the exposed bone may be a sign of 
bone metastasis (Migliorati et al., 2005). The appearance of the exposed bone had 
a yellow-white discoloration in an area of ulcerated mucosa in most of the 
clinical findings by Migliorati et al. No bleeding after probing suggested 
avascular osteonecrosis (Migliorati et al., 2005).
As previously discussed, bisphosphonate-associated ONJ is defined as an 
area of exposed bone in the maxillofacial region present for at least 8 weeks 
(Khosla et al., 2007)/(King & Umland, 2008). In the absence of exposed bone the 
signs and symptoms of ONJ cannot account for an accurate diagnosis (Khosla et
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alv 2007). King et al define the stage 1 of ONJ as one with no symptoms or signs
of infection, but marked by the presence of exposed necrotic bone. The clinical
findings by Migliorati et al describe the surface of the exposed bone in the early 
stage as smooth.
As the disease progresses to stage 2 ONJ the first signs of infection and 
pain are present besides the exposed necrotic bone (King & Umland, 2008). Pain 
appears from secondary infection of soft tissue or as a result of the trauma 
(Migliorati et al., 2005). As the necrosis progresses, the exposed necrotic bone 
tends to get more rough and irregular, with a bony surface that may cause pain 
of the surrounding soft tissue and tongue (Migliorati et al., 2005). Patients with 
stage 3 ONJ develop fracture, fistula or osteolysis in addition to stage 2 ONJ 
symptoms of pain and infection (King & Umland, 2008). Trauma and 
mastication may contribute to small fractures and to the rough surface of bone at 
this stage (Migliorati et al., 2005). If the lesion causes an injury in the neural 
tissue, patients may complain of numbness either in the mandible, maxilla or lips 
(Migliorati et al., 2005). In this case the infection must be carefully controlled and 
the tooth surrounding the necrotic area should be extracted (Migliorati et al..
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2005). Patients treated for this further complication were not healed for 
osteonecrosis, but had related symptoms alleviated (Migliorati et al., 2005).
Incidence
The incidence of bisphosphonate-associated ONJ varies greatly among 
patients who have a cancer malignancy or those undergoing treatment for 
osteoporosis and Paget's disease. In the general population, however, the 
incidence of ONJ is unknown (Khosla et al., 2007)/(Hess, Jeter, Benham-Hutchins, 
& Alberts, 2008). The incidence of ONJ in osteoporosis patients receiving 
bisphosphonate treatment is <1 in 100,000, and in between 1% and 10% in 
patients with malignancy (Hess et al., 2008).
Hoff et al estimated the frequency of ONJ in patients treated with 
bisphosphonates in an 8-year retrospective analysis of patients treated with 
bisphosphonates. This study included a statistical analysis of the charts of 3994 
patients treated between the years of 1996 and 2004 with zoledronic acid and 
pamidronate (Hoff et al., 2008). The time period coincides with the approval of 
zoledronic acid for these therapies (2001) and also the first report on the possible
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association of ONJ and bisphosphonates by Ruggiero (2003). The use of 
intravenous bisphosphonate has been very successful in the prevention of 
skeletal-related events in patients with breast cancer and multiple myeloma 
(Hoff et al., 2008). This cohort study evaluated the duration of the therapy, the 
dosage and the potency of the bisphosphonate as possible risk factors associated 
with ONJ (Hoff et al., 2008). It also estimated the cumulative incidence of ONJ 
based on the time of initiation of the bisphosphonate therapy. This study found 
no significant difference in age and sex of patients who developed ONJ. The 
results from this cohort study show that patients who had developed ONJ also 
suffered from bone metastasis for a longer period of time (5.22 yrs) if compared 
to cancer patients without ONJ (1.53 yrs) (Hoff et al., 2008). These patients were 
treated with bisphosphonates for a longer period of time and were also shown to 
receive higher doses of the drug (Hoff et al., 2008). The median dose of 
pamidronate given to patients who eventually developed ONJ was significantly 
higher than to those that did not develop the complication (1755 vs. 180mg), 
which is a 3 to 6 fold increase (Hoff et al., 2008). The same is true for zoledronic 
acid treatment (62 vs. 12mg), a 2 to 2.4 fold increase (Hoff et al., 2008). Patients 
not being treated with zoledronic acid were treated with pamidronate. The
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study treated 2288 patients of 3994 patients with pamidronate only. A total of
1180 patients were treated with zoledronic acid alone, and 526 patients were
taking pamidronate followed by zoledronic acid (Hoff et al., 2008). The incidence
of ONJ (76 /o) was higher in patients taking zoledronic acid than in those not 
taking it (42%) (Hoff et al., 2008).
For patients who were diagnosed with ONJ the analysis was based on the 
number of years it took from the initiation of the therapy to the ONJ diagnosis 
(Hoff et al., 2008). Patients taking bisphosphonates for breast cancer bone 
metastasis and multiple myeloma were analyzed separately as well (Hoff et al., 
2008). Patients who did not present any signs or symptoms of ONJ were 
analyzed based on the initiation date of the bisphosphonate therapy and the last 
check-up (Hoff et al., 2008).
Patients being treated for osteoporosis, Paget's disease and hypercalcemia 
of malignancy did not develop ONJ as a complication of the bisphosphonate 
therapy (Hoff et al., 2008). The incidence of ONJ was higher in patients with 
multiple myeloma (2.4%) and breast cancer (1.2 />) (Hoff et al., 2008). The 
cumulative dose of zoledronic acid or a combination of zoledronic acid and 
pamidronate contributed significantly to an increase in ONJ in cancer patients
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and multiple myeloma patients (Hoff et al., 2008). On a prospective series study 
with 252 patients the incidence of bisphosphonate associated ONJ increased with 
the duration of exposure to zoledronic acid as well (Bamias et alv 2005). The 
incidence of bisphosphonate associated ONJ in the first 4 to 12 months of therapy 
was of 1.5% and it increased to 7.7% after 37 to 48 months (Bamias et al., 2005). 
Zoledronic acid is the most potent of all bisphosphonates and it is much more 
potent than pamidronate as seen by the rank of potency: zoledronic acid > 
ibandronate > risedronate > alendronate > pamidronate > etidronate (Hoff et al., 
2008). It cannot be said, however, that zoledronic acid alone contributes to a 
greater incidence of ONJ as this complication has been associated with other risk 
factors (Hoff et al., 2008).
Another study by Mavrokokki et al identified cases of ONJ reported by a 
postal survey of Australian Oral and Maxillofacial Surgeons (OMS) between 2004 
and 2005. A second part of the study evaluated the frequency of ONJ in the 
population under bisphosphonate therapy by using the health care information 
reported by the Australian national health system, which has a good reputation 
for having a reliable database on dental health. The number of prescriptions for 
bisphosphonates is known by the Australian national health system, and the
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database was source of valuable information regarding prescriptions 
(Mavrokokki, Cheng, Stein, & Goss, 2007). An estimation of the percentage of 
dental treatments received and required dental extractions by Australians was 
done through the Dental Research Unit of the Australian Institute of Health of 
the Commonwealth Government of Australia (Mavrokokki et al., 2007).
According to Mavrokokki et al, 62.5% of Australians received dental 
treatment and 15.4% of them had dental extractions. The study was based on a 
survey given to the Australian and New Zealand Association of Oral and 
Maxillofacial Surgeons (ANZAOMS) (Mavrokokki et al., 2007). It provided a 
definition of ONJ in which the healing time was of 6 weeks as opposed to the 8 
weeks established by previous studies discussed.
The total number of prescription for bisphosphonates in Australian over 
the period of two years (2003 -  2005) was 2.83 million (Mavrokokki et al., 2007). 
The breakdown of prescription for different malignancies follows: 2.74 million 
for osteoporosis, 27,300 for Paget's disease, and 61,500 for bone malignancy. The 
frequency of ONJ was higher in patients with bone malignancy (1 in 114), and it 
was followed by Paget's disease (1 in 380), and osteoporosis (1 in 8,470). The 
total number of ONJ cases identified was 158 and the overall frequency was of 1
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in 2,030 cases (Mavrokokki et al., 2007). Dental extractions were a significant 
factor in the development of ONJ in 73% of the cases of patients treated with 
bisphosphonates. The most common sites for ONJ were: the mandible (64%), the 
maxilla (27%), and both sites (9%) (Mavrokokki et al., 2007). A difference 
between the Mavrokokki et al study and American studies is that the population 
size and the ability to collect information on the health system in Australia differ 
from the American system. It is easier to have more control over the reported 
information in a smaller country with an efficient national health system such as 
Australia. Another important distinction must be made regarding the different 
definition for the healing time for ONJ diagnosis. The American Society for 
Bone and Mineral Research established that (ASBMR) ONJ be classified as the 
presence of exposed bone in the maxillofacial region that did not heal in a period 
of 8 weeks. By reducing the healing period of 8 weeks to 6 weeks, it is likely that 
more reported cases of ONJ may be included in this Australian study.
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Associated Risk Factors
Among the complications associated with development of ONJ the 
following were the most common in 28 of the 29 patients (Hoff et al., 2008): 
dental extraction (16 patients), periodontal disease (14), mandibular or maxillary 
tori (10), denture induced trauma (3), intubation induced trauma (1), and trauma 
from the manipulation of dental implants (1) (Hoff et al., 2008). Thirteen of these 
patients were followed for more than 6 months, and an analysis indicated that 
within a period of 3 months after diagnosis all of them received zoledronic acid. 
(Hoff et al., 2008). A majority of the patients had been previously treated with 
pamidronate (10 of 13 patients) (Hoff et al., 2008). The study evaluated the 
effects of discontinuation of zoledronic. The first group of patients consisted of 8 
individuals who discontinued zoledronic acid, the second group of two patients 
decreased the frequency of zoledronic acid, and one individual took alendronate 
(70mg) weekly instead of zoledronic acid (Hoff et al., 2008). Two patients 
continued the zoledronic acid therapy with no changes (Hoff et al., 2008). The 
discontinuation of zoledronic acid contributed to the healing of one patient after 
10.6 months (Hoff et al., 2008). The replacement of zoledronic acid by
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alendronate weekly was successful for the healing of one patient after 9.5 months 
(Hoff et al., 2008). By reducing the dosing frequency of 4 mg infusion of 
zoledronic acid from monthly to every 3 months, one patient was healed after 3 
months (Hoff et al., 2008). The overall healing success of patients over a 3-year 
period was of less than 25% (Hoff et al., 2008). The results showed that none of 
the breast cancer patients had healed and three of the seven multiple myeloma 
patients had healed completely (Hoff et al., 2008). The conclusion of this cohort 
study is that the discontinuation of zoledronic acid does not affect healing (Hoff 
et al., 2008). One of the limitations of this study can be said to be the study 
design as a retrospective analysis of chart reviews. This type of study may give 
an estimate of the incidence, but the information collected is limited since a chart 
review does not allow lasting contact and observation to a patient at risk of the 
complication. Additionally, complete data may not be available. The assessment 
of the clinical course of ONJ was possible in 13 of 29 patients included in the 
cohort study and diagnosed with ONJ (Hoff et al., 2008). These numbers suggest 
that only half of the patients diagnosed with ONJ was followed. Although the 
patient pool (3994) was evaluated in the cohort study was large, only 29 cases of 
ONJ were identified, and approximately half of the identified cases was followed
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clinically. This study is another example of the small sample sizes that are 
commonly found in the published literature on osteonecrosis of the jaw. Small 
sample sizes pose a limitation to the quality of the research and should be 
supported by additional studies.
Risk Factors
Hess et al were interested in finding risk factors for ONJ in patients who 
did not have cancer, but were taking bisphosphonates. A systemic review of 
case reports for ONJ from 1996 to 2007 was the method chosen to develop a 
model for the possible causes and risk factors for ONJ in cancer free patients 
receiving bisphosphonates. Most of the cases identified of patients without 
cancer were osteoporosis patients (85 of 99 cases). Paget's disease was the 
second most common case of patients with ONJ (10 of 99 cases). Similarly, the 
mean age was 69.4 years old and the highest incidence of ONJ was in female 
87.3% (Hess et al., 2008). Unlike the study of Hoff et al in which no significant 
differences were found in age and sex of patients who developed ONJ, Hess et al 
suggests that the female sex and patients over 60 years old are at greater risk for
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ONJ. The demographics suggested by Mavrokokki et al based on Australian data 
shows that older patients with malignant bone disease are at higher risk for ONJ 
especially if under nitrogen containing bisphosphonate therapy for a longer 
period of time. In part this can be explained by fact that the incidence of 
osteoporosis is highest in females and Paget's disease is also common in the 
elderly.
A significant risk factor for ONJ has been shown to be recent dental 
procedure. The incidence of bisphosphonate related ONJ in patients with 
osteoporosis increased greatly in those who undergo dental procedures (Hess et 
al., 2008). The range of incidence in those without dental procedure is from 1 in 
1260 to 1 in 100,000. In those with dental procedure the incidence range 
increases from 1 in 296 to 1 in 1130 (Mavrokokki et al., 2007). Mavrokokki et al 
determined the number of patients requiring extractions by using the data 
provided by the Dental Research Unit of the Australian Institute of Health of the 
Commonwealth Government of Australia. The institute provided the percentage 
of patients that received dental care as well as the percentage of those requiring 
dental extraction in a year. The frequency of ONJ related to dental extraction 
was based on the number of Australian patients requiring extractions
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(Mavrokokki et al., 2007). The method of estimated frequency may be weak 
because an extrapolation of the South Australian data to Australia as a country 
does not give an accurate measurement of the risks of ONJ.
A great majority (88.9%) of the 63 patients with reporting dental 
information had undergone a dental procedure before the development of ONJ 
(Hess et al., 2008). Another common risk factor is the use of concomitant 
medication, and in this study 71% of the patients were taking bisphosphonates 
and at least one other medication that influenced bone turnover (Hess et al., 
2008). Among the most common medications taken concomitantly are: steroids 
(41.7%), diuretics (20.8%), and statins (16.7%) (Hess et al., 2008). Hoff et al 
evaluated the dosage and type of glucocorticoids that patients were taking and 
compared a group of patients who did not develop ONJ to an ONJ group. The 
patients under evaluation were part of a cohort study that included cancer 
patients and non-cancer patients. The effects of dexamethasone and prednisone 
were compared between the two groups (Hoff et al., 2008). In the non-ONJ 
group a total of 2840 patients were taking dexamethasone and 432 patients were 
receiving prednisone. In the ONJ group 21 patients were treated with 
dexamethasone and 2 patients were receiving prednisone (Hoff et al., 2008). The
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J group received a 2 fold higher dosage of dexamethasone, but the statistical 
difference was not significant to attribute an association between dexamethasone 
and ONJ (Hoff et al., 2008). .
Osteoporosis
The majority of the published studies are based on case reports of patients 
taking bisphosphonates for a cancer malignancy (Sambrook, Olver, & Goss, 
2006). Hess et al made a systemic review search of published case reports on 
non-cancer cases and focused on osteoporosis and Paget's diseases. Of 53 cases, 
62.4% reported dental care information, and 92.5% of those cases had a dental 
procedure before the development of ONJ (Hess et al., 2008). The percentage of 
patients taking between 1 to 5 medications that influenced bone turnover was 
also high 70.8% of the 24 cases (Hess et al., 2008). Steroids (41.7%) and diuretics 
(20.8%) were the most common medications taken concomitantly with 
bisphosphonates in these patients (Hess et al., 2008). The quality of the study is 
generally poor except for the clinical evidence presented from these case reports. 
The majority of the case reports include a very small number of cases on
45
osteoporosis, and one with highest reporting was done by Mavrokokki et al (24 
reported cases). Mavrokokki et al based their study on cases identified between 
2004 and 2005 in Australia by a postal survey of Australian Oral and 
Maxillofacial Surgeons (OMS). The study did not focus only on osteoporosis 
cases, but the incidence of ONJ was estimated based on prescription and dental 
extraction data using a national database. Osteoporosis patients under weekly 
oral alendronate developed ONJ in 0.01% to 0.04% of the cases (1 in 2,260 to 8,740 
patients). The frequency of ONJ was higher in patients that under went dental 
extractions with 0.09% to 0.34% of the cases (1 in 296 to 1,130 patients) 
(Mavrokokki et al., 2007).
Paget's Disease
The mean age of all 10 Paget's disease patients with ONJ was 77.5 years 
old. Of all 6 patients who had a dental procedure, four of them (67%) developed 
ONJ (Hess et al., 2008). Half of all patients were taking concomitant medication, 
and 80% of those were taking between 1 and 3 drugs that affected bone turnover 
(Hess et al., 2008). The risk factors for ONJ in non-cancer patients receiving
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\ 1 onates are similar to those of the cancer population (Hess et al., 2008).
V edures are the most common risk factors in both populations and are 
associated with 88.9% of the cases for non-cancer patients (Hess et al., 2008). The 
q ency of ONJ in Paget s disease patients on bisphosphonates without dental 
extractions is of 0.26 /o to 1.8% (1 in 56 to 380). The frequency of ONJ increases in 
Paget's disease patients who had dental extractions, 2.1% to 13.5% (1 in 7.4 to 48) 
(Mavrokokki et al., 2007). The duration of the bisphosphonate use was also 
shown to be a potential contributing factor and 93.5% of osteoporosis patients 
received the therapy for more than a year (Hess et al., 2008). Of the Paget's 
disease patients, 60% were receiving bisphosphonates for more than a year (Hess 
et al., 2008).
Hess et al demonstrated in this study that there are significant differences 
in the possible contributing risk factors for osteoporosis patients and Paget's 
disease patients. The frequency of patients taking concomitant medications that 
affect bone turnover was higher in Paget's disease patients (80%) in comparison 
to osteoporosis patients (69.6%). Another significant finding is that while 90% of 
osteoporosis patients had an additional underlying medical condition, the same 
was true for only 50% of Paget's disease patients. This study suggests that the
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risk factors for both conditions be analyzed separately. It also indicates that 
bisphosphonate alone is not a causal factor for ONJ since the underlying 
conditions, medications, dental procedures, and other factors combined may be 
associated with an increased risk for ONJ. The study points out that a healthy 
patient taking bisphosphonates is not likely to develop ONJ, which supports an 
association but a not a causal relationship of bisphosphonates. A limitation of 
this study, however, is that an analysis based exclusively on case reports tends to 
be biased to the abnormalities in question as there is no comparison group. The 
ONJ may be skewed since there is no denominator for the frequency of ONJ in 
the normal population. Another problem of systemic reviews of case reports is 
that the quality of the reports varies. Even though guidelines and definitions are 
established to include and exclude case reports, these types of studies may 




Patients receiving bisphosphonates should be informed of the importance 
of good dental hygiene for prevention of ONJ (King & Umland, 2008). Good 
dental care prevents periodontal disease, caries and delays the need for more 
invasive dental procedures. Before beginning the bisphosphonate therapy a 
thorough dental exam is advised (King & Umland, 2008). If dental extractions or 
oral surgeries are necessary it is recommended that the initiation of the therapy 
be delayed until complete healing occurs (King & Umland, 2008). The patient 
should be advised by the oncologist and dental care provider to report any signs 
of pain, discomfort, and tenderness in the gums and teeth (King & Umland, 
2008). Invasive dental procedures such as dental extractions should be avoided 
during treatment with intravenous bisphosphonate or taken care of before 
initiation of the therapy if possible (King & Umland, 2008). The American Dental 
Association recommends that patients taking oral bisphosphonates also follow 
these precautions even though the risk of developing ONJ is low for this group. 
(ADA, 2008). Although there has not been any evidence that discontinuation of 
bisphosphonates contributes to healing, the American Association of Oral and
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Surgeons (AAOMS) suggests that bisphosphonates be discontinued 
onths before and after surgery ("American Association of Oral and 
Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis 
of the jaws, 2007). Treatment with chlorhexidine 0.12% mouth rinses for 2 
months after surgery and antibiotics is recommended (King & Umland, 2008).
It is not clear whether interrupting bisphosphonate treatment for 
osteoporosis patients decrease the risk of developing ONJ (Khosla et al., 2007). A 
patient with bone metastasis may be at a lower risk for further skeletal-related 
complications after a brief interruption in the intravenous bisphosphonate 
therapy (Khosla et al., 2007). The risks of discontinuing bisphosphonates must be 
evaluated individually so that they don't outweigh the benefits for that patient. 
There is no evidence of the benefits of discontinuing bisphosphonates since most 
patients do not respond to the interruption of the treatment (Migliorati et al, 
2005)/(Hoff et al., 2008). As it will be explained later, the discontinuation of the 
treatment of bisphosphonates has not been shown to decrease the healing time 
nor prevent or improve ONJ after dental procedures (Hoff et al., 2008)/(Khosla et
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al, 2007).
of pain control and antibiotics is recommended for both 
cases and depending on the ON] severity. The AAOMS recommends the 
following:
Patients on stage 1 ONJ show no symptoms or signs of infection, but have 
exposed necrotic bone (King & Umland, 2008). A conservative treatment with 
antimicrobial chlorhexidine 0.12% mouth rinse to prevent infection is 
appropriate. Systemic antibiotics cannot control more than infection in the soft 
tissue and vital bone because this type of necrosis is avascular (Migliorati et al., 
2005). Attention should be given to the development of pain and signs of 
infection (King & Umland, 2008).
Patients on stage 2 ONJ in addition to exposed bone have pain and early 
signs of infection (King & Umland, 2008). Pain control should be treated with 
nonsteroidal anti-inflammatory drugs and penicillin is recommended for bone 
infections (King & Umland, 2008). Local debridement of necrotic bone may be
necessary to provide pain relief.
Patients on stage 3 ONJ may present pathologic fracture, fistula or
osteolysis (King & Umland, 2008). Besides treatment for pain and infection as
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described on stage 2 ONJ, they should undergo surgical removal of necrotic bone 
(King 6c Uinland, 2008). The management of patients of ONJ is difficult because 
suigical debridements are not completely effective and some necrotic bone may 
remain exposed (Ruggiero, Mehrolra, Rosenberg, & Engroff, 2004). In some 
patients healing does not occur and a larger necrotic bone develops, only 
aggravating the situation (Migliorati et al., 2005). Patients should be made aware 
of the risks of the surgery and the patient's oncologist should participate in the 
decision for the procedure (Migliorati et al., 2005). Only symptomatic patients 
with fractures and regions of highly infected necrotic bone should undergo 
surgical treatment (Ruggiero et al., 2004). In order to avoid invasive procedures 
and minimize trauma, Migliorati et al provided soft vinyl splints to cover the 
necrotic area (Migliorati et al., 2005). Previous studies have shown that 
hyperbaric oxygen therapy is not effective in treating this type of complication 
(Migliorati et al., 2005)/(Khosla et al., 2007).
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Data Reporting Limitations
The data reporting bisphosphonate associated ONJ is limited in many 
ways. The data on the topic is very limited because it is mostly based on case 
reports of the past few years. Therefore, bisphosphonates are known to be 
associated with ONJ as a complication, but there is no data on causality. In 2007 
the Journal of Bone and Mineral Research (JBMR) published an editorial defining 
the condition and recognizing the possible association of bisphosphonates with 
ONJ. Recommendations and guidelines for studies and future research were 
made to increase the quality of case reports and studies. One of the problems of 
some reports was the variation of the definition of the case. The American 
Society for Bone and Mineral Research (ASBMR) defines a confirmed and a 
suspected case of bisphosphonate-associated ONJ, but early reports do not 
necessarily follow this definition. Important historical and clinical information 
on the patient are also missing from some studies, thus decreasing the quality of 
the evidence presented (Khosla et al., 2007). More studies in vivo and in vitro are 
also crucial for understanding the role of bisphosphonates in ONJ, and that of 
other risk factors. Case reports alone tend to be biased to the abnormal condition
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ay make an association between two factors appear causative. The lack of 
a on the incidence of ONJ in the normal population gives a bad denominator 
to assess the actual rate of incidence (Khosla et al., 2007)/FDA, 2003). The quality 
of the evidence presented was classified as poor by the ASBMR, and the task 
force has recommended that future studies refer to their recommendations 
(Khosla et al., 2007). King et al point out that other possible risk factors 
associated with the complication were not consistently documented in many 
cases. This lack of consistency in reporting does not explain whether the risk 
factor was not part of the medical history of the patient or if due to incomplete 
reporting of the medical history (King & Umland, 2008). The medical history of 
patients with bisphosphonate associated ONJ included in many cases 
concomitant medications, underlying malignancy and multiple factors that could 
contribute to ONJ (Hess et al., 2008). The accuracy of the reporting of the history 
and clinical information is, therefore crucial to a correct diagnosis (Hess et al., 
2008) The actual frequency of ONJ and associated risk factors must be validated 
by additional cohort studies and animal models because case reports are more 
descriptive (King & Umland, 2008). Case reports are useful, as in the case of
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ng attention to new evidence and raise questions that the scientific 
community should further examine and address.
Future recommendations
Researchers must deeply investigate the risk factors for ONJ especially 
with other drugs that affect bone turnover since the mechanism of action of 
bisphosphonate has not been clearly elucidated. The development of animal 
models is crucial to the understanding of this complication once the 
administration of the drug can be controlled, and bone turnover may be 
monitored without posing a risk to the patient. The administration of 
bisphosphonates intravenous or orally, its bioavailability and cumulative effects 
can be better examined in an animal model. It is not clear why the incidence of 
ONJ in the mandible is higher than the maxilla, and more studies are necessary 
on the antiangiogenic effects of bisphosphonates and the vascularization in these 
sites. Although there has been reported an association of bisphosphonates to 
ONJ, there is no evidence yet of a causal relationship. It is possible that other 
anti-resorptive drugs induce a similar effect as bisphosphonates and may be
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associated with ONJ. An analysis of reports on the use of bisphosphonates is not 
enough, and more studies on these drugs, and ONJ is necessary.
The initiating event in the development of ONJ has not yet been clearly 
elucidated. One of the most common suggestions is that the anti-angiogenesis 
properties of bisphosphonates explain the development of avascular necrosis. 
The function of the bone and its vascularization is compromised once 
bisphosphonates interfere with osteoclast differentiation (Reiriz et al., 2008). The 
network of capillaries irrigating bone is compromised by dying and dead 
osteocytes that cannot be replaced to maintain the bone (Reiriz et al., 2008). Other 
scientists question this mechanism once the avascular osteonecrosis has shown 
preferential localization to the maxilla and mandible as opposed to other parts of 
the body (Landesberg et al., 2008).
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Conclusion
In 2003 reports by Marx and Ruggiero on reported cases of osteonecrosis 
of the jaw in patients taking bisphosphonates called the attention of the scientific 
community to a possible association of bisphosphonates to ONJ. The use of 
bisphosphonates to treat patients with bone metastasis and osteoporosis has been 
successful in preventing progression of the disease and skeletal-related events. 
Bisphosphonate therapy has greatly improved the lives of patients with bone loss 
suffering of spinal cord compression, pain and fractures. Some common side 
effects of bisphosphonates such as nausea and gastrointestinal discomfort have 
been discussed, and they are mostly mild. The route of administration of 
bisphosphonates and the potency of the drug have also been evaluated. Patients 
taking bisphosphonate intravenously for bone metastasis experience different 
side-effects than patients taking it orally for osteoporosis treatment. ONJ has 
been studied as a potentially more severe side-effect of the prolonged use of 
bisphosphonate. Some of the case reports have been later criticized for missing 
clinical and historical information on the patients. The incidence of ONJ, 
however, was missing in the first reports of ON] (Hoff et al„ 2008). A set of
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guidelines, recommendations and definition for ONJ have later been established 
by a task force on an editorial for the Journal of Bone and Mineral Research.
The incidence of ONJ in the general population is still unknown, and it 
makes difficult to assess the actual incidence in patients undergoing 
bisphosphonate therapy. The results of previous studies showed that it is 
necessary to separate the population of patients undergoing osteoporosis, Paget's 
disease and bone metastasis treatment with bisphosphonates when analyzing the 
effects of the drug in these patients. The incidence of ONJ in patients with 
osteoporosis and those with bone metastasis is significantly different. The 
incidence of ONJ in osteoporosis patients receiving bisphosphonate treatment is 
<1 in 100,000, and in between 1% and 10% in patients with malignancy (Hess et 
al., 2008). Bisphosphonates have been used for over ten years and future 
research must examine the cumulative effects of this class of drugs. As 
previously discussed, the incidence of bisphosphonate associated ONJ in the first 
4 to 12 months of therapy was of 1.5% and it increased to 7.7% after 37 to 48 
months (Khamaisi et al., 2007). More studies on the effects of bisphosphonate 
accumulation in bone especially in animal models may be very useful. The 
median dose of pamidronate given to patients who eventually developed ONJ
58
was 3 to 6 fold higher than in those who did not develop the complication (Hoff 
et al., 2008). Patients being treated with zoledronic acid who developed a 
complication also had 2 to 2.4 fold increase (Hoff et al., 2008). Pharmacogenetic 
studies using animal models will be useful to determine the accuracy of the 
reported incidence of ONJ. A study by Hoff et al reported a higher incidence of 
ONJ (76 /o) in patients taking zoledronic acid than in those not taking it (42%).
Future studies must also address the associated complications and risk 
factors that may contribute to ONJ. It is not clear how strongly associated 
bisphosphonates are to the development of ONJ, but this complication is very 
likely multifactorial. One of the major risk factors for ONJ discussed has shown 
to be invasive dental procedures such as extractions and invasive surgery. Hess 
et al reported that a great majority (88.9%) of the 63 patients with reporting 
dental information had undergone a dental procedure before the development of 
ONJ (Hess et al., 2008). According to Coleman et al the incidence of ONJ 
development is complicated by dental extraction or jaw surgery in 75% of the 
cases. Other contributing factors such as concomitant use of cancer medications 
and corticosteroids have also been indicated (Coleman, 2008). In a study by Hess 
et al 71% of the patients were taking bisphosphonates and at least one
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medication that influenced bone turnover (Hess et al., 2008). More studies must 
determine the most likely contributing factors to the development of 
ONJ and their mechanism of action. The pathogenesis of ONJ is still not clear, 
and the most likely contributing factors reported and studied focused on the 
inhibition of angiogenesis by high doses of N-BPs, invasive dental procedure, 
trauma, infection, oversuppression of bone turnover in the jaw and concomitant 
medication for underlying diseases (Coleman, 2008).
Among the preventive recommendations it is important to emphasize that 
dentist and oncologists must inform their patients of a possible risk for 
development of ONJ. Patients should be aware of the first signs and symptoms 
of ONJ and report to the dental professional the use of bisphosphonates and 
changes in medication. Good oral hygiene must accompany the treatment with 
bisphosphonates and in case of surgery patients must be made aware of the risks 
of incomplete healing. Although there has not been any evidence that 
discontinuation of bisphosphonates contributes to healing, the American 
Association of Oral and Maxillofacial Surgeons (AAOMS) suggests that 
bisphosphonates be discontinued for 3 months before and after surgery (King & 
Umland, 2008). It is not possible to determine from the reported cases and
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studies the pathogenesis of ONJ and the mechanisms of action of 
bisphosphonates that may lead to ONJ. It is important, however, to follow the 
recommendations and guidelines established by the American Society for Bone 
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